U.S. markets open in 2 hours 45 minutes

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7400-0.1000 (-5.43%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close1.8400
Open1.8500
Bid0.0000 x 1100
Ask0.0000 x 1800
Day's Range1.6500 - 1.8600
52 Week Range0.8500 - 3.5400
Volume522,695
Avg. Volume1,177,431
Market Cap51.934M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.6990
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.31
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House
    Newsfile

    Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House

    New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to Texas law enforcement agencies, were intercepted before delivery on Thursday. That news helped focus attention toward Soligenix's RiVax® program, which is considered the leading ricin-poisoning vaccine program in the ...

  • Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens
    PR Newswire

    Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and Marburg viruses) and their thermostabilization. The article, authored by collaborators at the University of Colorado, University of Hawaiʻi at Mānoa (UHM) and Soligenix, is titled, "Preservation of Quaternary Structure in Thermostable, Lyophilized Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays" and has been accepted for publication in the Journal of Pharmaceutical Sciences. A copy of manuscript has been made available here.

  • SNGX: Update and Q&A on COVID-19 Vaccine Candidate CiVax™…
    Zacks Small Cap Research

    SNGX: Update and Q&A on COVID-19 Vaccine Candidate CiVax™…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Update on COVID-19 Vaccine Candidate CiVax™ On September 10, 2020, Soligenix, Inc. (NASDAQ:SNGX) held a webinar to provide an update on the COVID-19 vaccine landscape and the company’s COVID-19 vaccine candidate CiVax™. According to the World Health Organization ( WHO ), as of Sep. 9, 2020 there are currently 35